A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmakodynamics and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
This is a first-in-human, open-label, phase 1 dose escalation study. AMG 427 will be administered as an intravenous (IV) infusion in adult subjects with relapsed/refractory AML. The study will be conducted at approximately 7 sites in the United States (US), Australia, France, and Germany. Additional countries or sites may be added if necessary.